Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory

US Treasury Drafts Pharma China Investment Rules

Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
15
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The rules would preserve billions of dollars in US-China pharmaceutical licensing deals, supporting valuations for US drugmakers like Pfizer and Bristol Myers Squibb and providing capital to Chinese biotech firms such as Jiangsu Hengrui and Innovent Biologics. Uncertainty remains as the rules are not finalized and face opposition from lawmakers and smaller biotech companies, which could introduce volatility in the sector.

pharmaceutical biotechnology investment

The United States — United States Department of the Treasury is drafting rules governing US pharmaceutical companies' investments in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people briefed on the process. The rules would allow investment in promising new drugs developed by Chinese companies as long as they are not related to pathogens or weaponizable biotechnology. This approach departs from the Trump administration's tightening of business with China in other industries under new national security legislation and is looser than restrictions sought by some lawmakers. The rules have not been finalized and could change, particularly if Donald Trump weighs in. Pfizer and other major drugmakers have lobbied against broad restrictions, arguing they would cut US companies off from a fast-growing source of new medicines. Pfizer CEO Albert Bourla said he discussed China and national security concerns with Scott Bessent, Marco Rubio and representatives of the United States — United States Department of Health and Human Services. Smaller biotech firms including Ginkgo Bioworks and its CEO Jason Kelly have advocated for restrictions, warning of strategic dependence on China. Lawmakers John Moolenaar and Debbie Dingell are co-sponsoring a bill for tighter Treasury regulation of biotechnology-related investments, licensing agreements and joint ventures involving Chinese companies. Jake Auchincloss opposes curbing US spending in the sector. Outside licensing deals in Chinese biotech were worth $115 billion last year, according to GlobalData. Xi Jinping is due to meet with Trump in the US next week, and Treasury is unlikely to unveil new rules before that meeting.

govactor
Treasury is drafting the rules and faces competing lobbying from drugmakers and lawmakers over the scope of restrictions.
Importance 90.0 Sentiment 5.0
cnt
The US is drafting the investment rules through its Treasury Department, balancing national security concerns against pharmaceutical industry interests.
Importance 85.0 Sentiment 10.0
cnt
Chinese biotech companies stand to benefit from continued US investment and licensing deals, though the rules remain under negotiation.
Importance 80.0 Sentiment 15.0
stock
Pfizer has lobbied against broad restrictions and announced an up to $10.5 billion collaboration with Innovent Biologics covering 12 oncology programs.
Importance 75.0 Sentiment 20.0
per
The Pfizer CEO publicly argued that licensing Chinese medicines does not create national security concerns and should not be restricted.
Importance 60.0 Sentiment 15.0
per
The Treasury Secretary met with Pfizer and other drugmakers as they argued against broad restrictions on Chinese drug development investments.
Importance 55.0 Sentiment 5.0
stock
Bristol Myers Squibb signed a partnership with Jiangsu Hengrui worth up to $15.2 billion this year, a deal type the draft rules would likely preserve.
Importance 55.0 Sentiment 20.0
per
The President could weigh in on the draft rules, which remain subject to change, and is due to meet Xi Jinping next week.
Importance 50.0 Sentiment 5.0
stock
The Chinese drugmaker signed a partnership with Bristol Myers Squibb worth up to $15.2 billion, benefiting from continued US licensing activity.
Importance 50.0 Sentiment 20.0
stock
The Chinese biotech firm announced an up to $10.5 billion collaboration with Pfizer covering 12 oncology programs.
Importance 50.0 Sentiment 20.0
per
The Chinese President is due to meet Donald Trump in the US next week, with Treasury unlikely to unveil new rules before the meeting.
Importance 45.0 Sentiment 10.0
stock
The biotech company and its CEO have lobbied Treasury for restrictions, arguing US and European pharma will suffer from continued outbound investment to China.
Importance 45.0 Sentiment -10.0
per
The Representative asked Treasury to use the COINS Act to crack down on pharmaceutical transactions and is co-sponsoring a bill for tighter regulation.
Importance 45.0 Sentiment -5.0
per
The Secretary of State discussed China and national security concerns with Pfizer CEO Albert Bourla.
Importance 40.0 Sentiment 0.0
per
The Ginkgo Bioworks CEO met with Treasury officials to argue against strategic dependence on China for innovative drugs.
Importance 40.0 Sentiment -10.0
+ 6 more entities View on Dashboard
United States strategic rival ↔ China The United States perceives China as a strategic rival, actively implementing sanctions and export controls, while addre
United States related ↔ Pfizer
China related ↔ Pfizer
China related ↔ Scott Bessent
China related ↔ Donald Trump
Pfizer related ↔ Donald Trump
Scott Bessent agent ↔ Donald Trump Scott Bessent serves as the Treasury Secretary under President Donald Trump, acting as a key ally and implementer of his
+ 1 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.